药械

订阅

MedSci主页 / 所有栏目 / 药械

桑国卫：“重大新药创制”专项的进展与“十三五”对临床试验平台的要求

2015-12-27 桑国卫 凯卓科技

新药桑国卫
关注

“重大新药创制”专项的进展与“十三五”对临床试验平台的要求（节选）

“重大新药创制”专项的进展与“十三五”对临床试验平台的要求（节选）





















版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047835, encodeId=3a2c204e83556, content=<a href='/topic/show?id=c84c95e676b' target=_blank style='color:#2F92EE;'>#重大新药创制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95767, encryptionId=c84c95e676b, topicName=重大新药创制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Dec 09 08:55:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907268, encodeId=0a5e190e2680c, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 02 11:55:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49538, encodeId=9e9349538b4, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:23:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49523, encodeId=d492495236b, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49524, encodeId=5c8349524f7, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49376, encodeId=9d36493e6c5, content=总结！, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Dec 27 14:14:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2016-12-09 mgqwxj

    #重大新药创制#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2047835, encodeId=3a2c204e83556, content=<a href='/topic/show?id=c84c95e676b' target=_blank style='color:#2F92EE;'>#重大新药创制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95767, encryptionId=c84c95e676b, topicName=重大新药创制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Dec 09 08:55:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907268, encodeId=0a5e190e2680c, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 02 11:55:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49538, encodeId=9e9349538b4, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:23:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49523, encodeId=d492495236b, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49524, encodeId=5c8349524f7, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49376, encodeId=9d36493e6c5, content=总结！, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Dec 27 14:14:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2016-06-02 hongbochen

    #十三五#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2047835, encodeId=3a2c204e83556, content=<a href='/topic/show?id=c84c95e676b' target=_blank style='color:#2F92EE;'>#重大新药创制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95767, encryptionId=c84c95e676b, topicName=重大新药创制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Dec 09 08:55:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907268, encodeId=0a5e190e2680c, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 02 11:55:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49538, encodeId=9e9349538b4, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:23:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49523, encodeId=d492495236b, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49524, encodeId=5c8349524f7, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49376, encodeId=9d36493e6c5, content=总结！, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Dec 27 14:14:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2047835, encodeId=3a2c204e83556, content=<a href='/topic/show?id=c84c95e676b' target=_blank style='color:#2F92EE;'>#重大新药创制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95767, encryptionId=c84c95e676b, topicName=重大新药创制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Dec 09 08:55:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907268, encodeId=0a5e190e2680c, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 02 11:55:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49538, encodeId=9e9349538b4, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:23:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49523, encodeId=d492495236b, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49524, encodeId=5c8349524f7, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49376, encodeId=9d36493e6c5, content=总结！, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Dec 27 14:14:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2015-12-27 wzf990214

    有意思

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047835, encodeId=3a2c204e83556, content=<a href='/topic/show?id=c84c95e676b' target=_blank style='color:#2F92EE;'>#重大新药创制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95767, encryptionId=c84c95e676b, topicName=重大新药创制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Dec 09 08:55:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907268, encodeId=0a5e190e2680c, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 02 11:55:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49538, encodeId=9e9349538b4, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:23:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49523, encodeId=d492495236b, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49524, encodeId=5c8349524f7, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49376, encodeId=9d36493e6c5, content=总结！, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Dec 27 14:14:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2015-12-27 wzf990214

    赞一个

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2047835, encodeId=3a2c204e83556, content=<a href='/topic/show?id=c84c95e676b' target=_blank style='color:#2F92EE;'>#重大新药创制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95767, encryptionId=c84c95e676b, topicName=重大新药创制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Dec 09 08:55:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907268, encodeId=0a5e190e2680c, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jun 02 11:55:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49538, encodeId=9e9349538b4, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:23:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49523, encodeId=d492495236b, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49524, encodeId=5c8349524f7, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Dec 27 19:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49376, encodeId=9d36493e6c5, content=总结！, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Dec 27 14:14:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2015-12-27 lovetcm

    总结！

    0

相关资讯

2015年美国FDA新药审批一览，批准41个新分子实体

截止2015年12月9日，2015年FDA药品审评与研究中心（CDER）受理36份新分子实体申请；批准41个新分子实体，其中包括19个罕见病用药。首轮获批率创历史新高。完成PDUFA V规定的新药绩效指标。本文以图文并茂的方式，对2015年CDER新药审批情况作全景式的展现。 2015年12月14日，FDA CDER新药办公室主任J. K. Jenkins博士在2015 CMS/FDA峰会上

这些新药或将改变这4种疾病的治疗用药格局

Tharaldson指出即将在2015年后期及2016年批准上市的几种专科药将可能对以下4种疾病的治疗产生深深影响，下面我们来详细看一下是哪四种疾病。10月27日在佛罗里达奥兰多召开的一个医药行业学术会议中，快捷方药（Express Script）公司新兴疗法资深临床顾问、药学博士AimeeTharaldson在会议上就处于研发中的几种专科药做了相关介绍。她指出了几个可能在2016年被批准的专

新药研发：成本过高盈利慢 越来越深的痛？

近日，全球四大会计事务所之一的德勤会计事务所发布的一项调查表示，制药行业研发投入回报过低，已经不足以维持企业今后对产品线的投资了。 这份针对16家制药企业的调查表明，尽管去年美国新上市的药物达到了43个，已经创下了新的纪录，然而这一光鲜的数字却掩盖了潜在的问题——研发的转化效率过低。 这项名为《2015制药行业研发创新回报评估》的调查显示，2015年全球前12大药企的研发回报率跌至4.2%

Lab invest：新药可预防致命核辐射

新研究发现对抗致命的辐射有了新突破。在核辐射暴露后24小时内，一种再生肽可以帮助显著提高小鼠的生存时间。目前这项研究出版在自然出版集团的杂志Laboratory Investigation上。德州大学医学分部研究作者Carla Kantara是生物化学和分子生物学博士后，他说当小鼠处于致命辐射中24小时内单次注入肽类药物TP508似乎可以大大增加小鼠生存并延迟死亡。核事故的威胁可能杀死或伤害成千上

Acta Neuropathol：新药或可改善阿尔兹海默症或其他脑部疾病

神经病理学中心的Armin Giese教授和研究人员分析了一种新的物质，可以作为一个原型发展的药物来治疗阿尔茨海默氏症和其他脑部疾病。该物质被称为“anle138b”，这种物质可以改善小鼠疾病症状并提高它们的认知。科学家们报告这些发现在《Acta Neuropathologica》杂志上。 “我们已经发现，这种物质能防止tau蛋白的聚合。此聚合是阿尔茨海默氏症和其他脑部疾病的典型的表现，被称

Cancer Cell：治疗新潜力药物—让癌细胞“得瑟”而死

图：左为对照组癌细胞，右为经MCB-613处理的癌细胞癌细胞的分裂繁殖速度已经超乎正常，那如果给点刺激，让癌症细胞长得再快点会出现什么情况？——答案是会“得瑟”而死。这种过度刺激肿瘤生长关键蛋白的候选药物或将作为一种新的方法治疗多种癌症。该方法的工作原理是让癌细胞在应激边缘“不堪重负”而死。这篇文章发表在最新的Cancer Cell杂志。本文资深作者，David Lonard是美国贝勒医学院细胞